1. Cybin's CMO will participate in the Cantor Global Healthcare Conference. 2. The event is scheduled for September 5, 2025, at 10:20 a.m. ET. 3. Cybin is revolutionizing mental healthcare with innovative treatment options. 4. CYB003 is in Phase 3 for major depressive disorder. 5. CYB004 is being studied for generalized anxiety disorder in Phase 2.
Dr. Inamdar's presence at a major conference increases investor interest. Historically, positive presentations have led to stock price surges.
The article highlights a key leadership figure's involvement in a significant upcoming event. This likely attracts investor interest and media coverage, positively impacting stock performance.
The upcoming conference is imminent, likely influencing CYBN's short-term stock performance. Similar past events have shown short-term spikes in related biotech stocks.
Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Amir Inamdar, Cybin's Chief Medical Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference, taking place September 3-5, 2025.
Dr. Inamdar's fireside chat will be webcast live on Friday, September 5, 2025, at 10:20 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page.
About Cybin
Cybin® is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250903716914/en/
Investor Contact:
Candice Masse
astr partners
Managing Director
(978) 879-7273
candice.masse@astrpartners.com
Media Contact:
Gabriel Fahel
Chief Legal Officer
Cybin Inc.
1-866-292-4601
irteam@cybin.com – or – media@cybin.com